Controlled-release doxazosin in the treatment of benign prostatic hyperplasia.

Purpose: To evaluate the effectiveness and safety of controlled-release doxazosin for benign prostatic hyperplasia (BPH). Scope: In this open-label, noncontrolled, observational surveillance study, 3684 men with BPH received 4–8 mg of controlled-release doxazosin gastrointestinal therapeutic system (GITS) for 6 months; 3283 (89.1%) patients completed the trial. Changes in urinary symptoms and quality of life were assessed using the International Prostate Symptom Score (IPSS). Blood pressure and adverse events were assessed. Conclusion: After 6 months’ treatment with doxazosin GITS resulted in significant improvements in IPSS. BP was reduced only in hypertensive patients. Doxazosin, GITS was well tolerated. Prostate Cancer and Prostatic Diseases (2005) 8, 375–380. doi:10.1038/sj.pcan.4500820; published online 1 November 2005